Emerging evidence · Grade B
Survodutide
Survodutide (BI 456906)
Score
74 / 100
Cadence
Once weekly
Class
GLP-1 / glucagon
Status
Investigational
TL;DR
01
An investigational once-weekly GLP-1 and glucagon receptor dual agonist (BI 456906) from Boehringer Ingelheim and Zealand Pharma — the same dual-agonist mechanism as mazdutide.
02
In a phase 2 obesity trial, the top dose (4.8 mg) produced about 14.9% weight loss at 46 weeks versus 2.8% with placebo.
03
Uniquely in the class, it also has positive phase 2 liver data: in MASH (fatty liver disease), 62% at the 4.8 mg dose achieved histologic improvement without worsening fibrosis, versus 14% on placebo.
04
Tolerability is a real question mark — gastrointestinal side effects were common (nausea up to 66% in the liver trial) and only about 60% of the obesity-trial participants completed 46 weeks.
05
It is investigational everywhere: no approval, and phase 3 trials (for both obesity and MASH) are the next step. Long-term cardiovascular and hepatic safety of glucagon agonism is not yet established.
Wt loss (phase 2, 4.8 mg)
−14.9%
Lancet D&E 2024 · 46 wk
Wt loss (2.4 mg)
−12.5%
Lancet D&E 2024 · 46 wk
MASH improvement (4.8 mg)
62%
vs 14% placebo · NEJM 2024
Fibrosis ≥1 stage (4.8 mg)
36%
vs 22% placebo · NEJM 2024
46-wk completion (obesity)
~60%
high GI-related dropout
Part 01 · How it works
Mechanism.
Survodutide activates two receptors at once. Through the GLP-1 receptor it blunts appetite and slows the stomach, like semaglutide. Through the glucagon receptor it nudges the body to burn more energy and mobilize fat from the liver — which is also why it shows up as a possible treatment for fatty liver disease, not just obesity. The glucagon arm is the differentiator and the risk: it's the same hormone that raises blood sugar when fasting, so its long-term effects have to be watched.
One dial turns down how much you eat; a second turns up how much fuel your body burns and how much fat the liver lets go of. Survodutide turns both — with the second dial being the one that needs careful long-term monitoring.
GLP-1R agonism
Agonist at the GLP-1 receptor — glucose-dependent insulin secretion, delayed gastric emptying, appetite suppression.
Glucagon receptor agonism
Co-agonist at the glucagon receptor, increasing energy expenditure and driving hepatic fat mobilization — the basis for its MASH investigation.
Dual indication
Studied for both obesity and metabolic dysfunction-associated steatohepatitis (MASH), an unusual dual track in the incretin class.
Once-weekly dosing
Long-acting design supporting once-weekly subcutaneous administration; trials use extended dose-escalation to limit GI effects.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Survodutide has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Escalation
→ 2.4–4.8 mg
Phase 2 used up to a 20-week escalation to reach the maintenance dose and limit GI effects.
TARGET
Maintenance
2.4–4.8 mg (obesity); up to 6.0 mg (MASH)
Once-weekly subcutaneous; higher doses gave more effect but more nausea.
·
Doses below are values from published phase 2 trials, not instructions. Survodutide is investigational and not approved.
·
Trials used unusually long dose-escalation specifically because the glucagon component adds to GI intolerance.
·
Studied cadence is once weekly by subcutaneous injection.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Nausea
Highest in the MASH trial (vs 23% placebo); peaks during escalation.
up to 66%
Diarrhea
Common (vs 23% placebo); generally mild-to-moderate.
~49%
Vomiting
Notably higher than placebo (4%); a driver of dropout.
~41%
Gastrointestinal disorders (overall)
In the obesity trial (vs 42% placebo); the dominant tolerability issue.
~75%
Decreased appetite
Expected on-mechanism effect.
Common
Serious · rare
Serious adverse events
In the MASH trial, serious-AE rates were similar to placebo — the concern is tolerability, not acute serious harm.
~8% vs 7% placebo
Increased heart rate (glucagon effect)
A recognized consideration for glucagon co-agonism; long-term cardiovascular data pending.
Not quantified here
Hepatic effects
Glucagon agonism affects hepatic metabolism; the MASH program is directly evaluating liver outcomes.
Under study
Absolute · do not use
×
Personal or family history of medullary thyroid carcinoma
×
Multiple endocrine neoplasia syndrome type 2 (MEN2)
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to survodutide or any component
×
History of pancreatitis
×
Severe gastrointestinal disease (gastroparesis)
Relative · discuss first
!
Pregnancy or breastfeeding — no adequate human data
!
History of pancreatitis — discuss with GI / endocrinology before any incretin-class agent
!
Poor tolerance of GI side effects — attrition in trials was substantial
!
Significant cardiovascular disease — glucagon agonism can raise heart rate; long-term CV safety unproven
!
Anyone seeking an approved therapy — survodutide is investigational everywhere
Interactions
Insulin
Increased risk of hypoglycemia; insulin dose reduction likely required
Major
Sulfonylureas
Additive hypoglycemic effect; dose reduction may be necessary
Major
Oral medications with narrow therapeutic index
GLP-1/glucagon dual agonism delays gastric emptying, potentially altering absorption of oral medications
Moderate
Other GLP-1 receptor agonists
Additive GI and pancreatic effects; should not be combined
Major
Labs to monitor
HbA1c
Baseline and every 3 months
GLP-1/glucagon dual agonist — glycemic monitoring
Lipase & Amylase
Baseline and every 3 months
Pancreatitis screening (GLP-1 class concern)
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver function (MASH indication); kidney function
ALT & AST
Baseline and monthly
Specific liver enzymes for MASH/NASH monitoring
Lipid Panel
Baseline and every 3 months
Glucagon component affects lipid metabolism
Thyroid Panel (TSH, Free T4)
Baseline and every 6 months
GLP-1 class thyroid concern
Part 04 · Evidence
How strong is the evidence?
74
Grade B
Grade B. Two well-conducted phase 2 trials — one in obesity, one in MASH — give survodutide a stronger-than-typical Emerging case, and the liver data is genuinely novel. It is held at B because efficacy stops at phase 2, tolerability/dropout is a real concern, nothing is approved, and glucagon-agonism long-term safety is unproven.
Mechanistic plausibility
GLP-1/glucagon co-agonism is coherent; the glucagon arm plausibly explains both weight and liver-fat effects.
82
Human evidence
Two phase 2 RCTs (obesity + MASH) with clear dose-response; no phase 3 readout and high obesity-trial dropout temper confidence.
74
Safety & tolerability
GI-heavy (nausea up to 66%); ~40% did not complete the 46-week obesity trial. Serious-AE rate similar to placebo.
70
Durability
46–48-week data only; no maintenance or outcomes evidence.
66
Independence
Both pivotal trials Boehringer Ingelheim-sponsored; no independent replication yet.
58
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2024
The Lancet Diabetes & Endocrinology Industry funded
Survodutide for obesity — dose-finding phase 2 trial
Dose-dependent weight loss to −14.9% at 4.8 mg (−12.5% at 2.4 mg) vs −2.8% placebo. GI adverse events in 75% of survodutide recipients; only ~60% completed 46 weeks.
RCT, 46 wk, double-blind, placebo-controlled (0.6–4.8 mg) · n = 387 · Funded by Boehringer Ingelheim; substantial discontinuation (some COVID-related) and rapid escalation complicate the tolerability read.
PMID 38330987 ↗
High
02
2024
New England Journal of Medicine Industry funded
Survodutide in MASH and fibrosis — phase 2 trial
Histologic MASH improvement without worsening fibrosis in 47/62/43% (2.4/4.8/6.0 mg) vs 14% placebo; fibrosis improved ≥1 stage in ~34–36% vs 22%. Nausea 66% vs 23%, vomiting 41% vs 4%.
RCT, 48 wk, double-blind, placebo-controlled (2.4 / 4.8 / 6.0 mg) · n = 293 · Funded by Boehringer Ingelheim; biopsy-based endpoints in a phase 2 population — supportive of, not confirmatory for, a MASH indication.
PMID 38847460 ↗
High
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Gastrointestinal burden and high early dropout
Safety signal Lancet D&E (phase 2 obesity) · 2024
In the phase 2 obesity trial, 75% of survodutide recipients had gastrointestinal adverse events and only about 60% completed the 46-week course — a markedly higher attrition than seen with the approved once-weekly agents.
What this means: The headline weight loss comes from participants who tolerated the drug; real-world effectiveness depends on whether the GI burden can be managed with slower titration. Dropout at this level is a genuine caution.
PMID 38330987 ↗
02
Everything is phase 2, and long-term glucagon safety is unproven
Mechanism limit NEJM (phase 2 MASH) · 2024
Survodutide's entire human evidence base is phase 2, with biopsy endpoints rather than clinical outcomes, and nothing is approved anywhere. The glucagon arm that differentiates it also carries the least-characterized long-term cardiovascular and hepatic risk; no outcomes trial has reported.
What this means: Promising and novel, but early. Confirmation depends on phase 3 trials that have not yet read out; treat current numbers as directional.
PMID 38847460 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Investigational
Not FDA-approved; in phase 3 development for obesity and MASH. No legal consumer product.
N/A
European Union
Investigational
Not approved; no consumer access.
N/A
United Kingdom
Investigational
Not approved; no consumer access.
N/A
Canada
Investigational
Not approved; no consumer access.
N/A
The Peptide Column takes no affiliate commission from any source. Survodutide is an investigational drug — not approved or legally available as a consumer product anywhere. Any material sold to individuals as "survodutide" is unapproved and unregulated.
Part 07 · Your appointment
Questions to bring.
01
How does survodutide compare to tirzepatide or semaglutide for weight loss in terms of efficacy and side effects?
02
Is survodutide available in any trials I might qualify for given my metabolic history?
03
Does the glucagon component pose any risk for people with or without diabetes?
04
What is the expected approval timeline and how does it compare to already-approved agents?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Survodutide for obesity — dose-finding phase 2 trial · The Lancet Diabetes & Endocrinology, 2024 · PMID 38330987 ↗
- 02. Survodutide in MASH and fibrosis — phase 2 trial · New England Journal of Medicine, 2024 · PMID 38847460 ↗
- 03.
- 04.
- 05.